Premium
Low‐Dose IL‐2 for In Vivo Expansion of CD4 + and CD8 + Regulatory T Cells in Nonhuman Primates
Author(s) -
Aoyama A.,
Klarin D.,
Yamada Y.,
Boskovic S.,
Nadazdin O.,
Kawai K.,
Schoenfeld D.,
Madsen J. C.,
Cosimi A. B.,
Benichou G.,
Kawai T.
Publication year - 2012
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2012.04133.x
Subject(s) - in vivo , foxp3 , medicine , cd8 , immunology , immunotherapy , transplantation , regulatory t cell , immune system , cancer immunotherapy , cancer research , il 2 receptor , t cell , biology , microbiology and biotechnology
IL‐2 is a known potent T cell growth factor that amplifies lymphocyte responses in vivo . This capacity has led to the use of high‐dose IL‐2 to enhance T cell immunity in patients with AIDS or cancer. However, more recent studies have indicated that IL‐2 is also critical for the development and peripheral expansion of regulatory T cells (Tregs). In the current study, low‐dose IL‐2 (1 million IU/m 2 BSA/day) was administered to expand Tregs in vivo in naïve nonhuman primates. Our study demonstrated that low‐dose IL‐2 therapy significantly expanded peripheral blood CD4 + and CD8 + Tregs in vivo with limited expansion of non‐Treg cells. These expanded Tregs are mainly CD45RA − Foxp3 high activated Tregs and demonstrated potent immunosuppressive function in vitro . The results of this preclinical study can serve as a basis to develop Treg immunotherapy, which has significant therapeutic potential in organ/cellular transplantation.